Acute Renal Failure Therapeutics Market is Segmented By Disease Indication (Pre-renal Kidney Failure, Post-renal Kidney Failure, Intrinsic Kidney Failure), By Treatment (Medications/ Drug Therapy, Dialysis, Others), By End-User (Hospitals, Clinics, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Acute Renal Failure Therapeutics Market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR 8.1% during the forecast period (2023-2030).
Market Dynamics
| Metrics | Details |
| Market CAGR | 8.1% |
| Segments Covered | By.Disease Indication, By Treatment, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
A condition in which the kidneys lose their ability to filter waste from the bloodstream. When kidneys lose their filtering ability, dangerous levels of waste can build up, and blood's chemical makeup can become unbalanced. Acute kidney failure, also known as acute renal failure or acute kidney injury, occurs quickly, usually within a few days.
Acute Renal Failure Therapeutics Market Dynamics
The factors influencing the global acute renal failure therapeutics market are the increasing research and development and the growing prevalence of acute renal failure.
The increasing research and development is expected to drive the market growth
A condition in which the kidneys lose their ability to filter waste from the bloodstream. When kidneys lose their filtering ability, dangerous levels of waste can build up, and blood's chemical makeup can become unbalanced. Acute kidney failure, also known as acute renal failure or acute kidney injury, occurs quickly, usually within a few days. Early goal-directed therapy aimed at improving renal (and other organs) perfusion has shown to be effective in treating ARF, and tight blood glucose control reduces the need for RRT. Antiendothelin antibodies, oxygen-free radical scavengers, and inhibitors of inducible nitric oxide synthetase are some of the more specific experimental treatments being tested to reduce renal damage caused by sepsis. Renal perfusion may be improved by infusions of atrial natriuretic peptide (ANP) or a synthetic analogue anaritide, and recombinant erythropoietin can reduce ischaemic renal injury in an animal model. Bioartificial kidneys as a renal replacement modality, a combination of a hemofilter and renal tubular cells designed to reduce circulating pro-inflammatory mediators, and possible stem cell therapy to improve native kidney recovery could be therapeutic strategies in the future. AKI is currently treated in a supportive manner. Recent advances in the understanding of renal injury and repair signaling pathways in preclinical models, on the other hand, have enabled the development of a number of promising pharmaceuticals that are currently being tested in human clinical trials. Anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, Heme Arginate), vasodilators (Levosimendan), apoptosis inhibitors (QPI-1002), and restorative agents (recAP, AB103, ABT-719) are a few examples (THR-184, BB- 3, MSCs). Given the complex multi-factorial pathophysiology of human AKI, any single agent is unlikely to produce a profound and consistent beneficial response. Any future pharmacotherapy for AKI is expected to be individualised based on the aetiology and primary mechanism of action. Different combinations of agents will most likely be required for different clinical scenarios.
Lack of knowledge of acute renal failure is expected to hamper the market growth
Some people's kidneys suddenly stop working. The kidneys abruptly stop performing their vital functions of excreting excess fluid and salts and removing waste. When the kidneys go on strike, the body accumulates dangerous levels of fluid, salts, and wastes. The person's life is jeopardised without functioning kidneys.
This condition is known as acute (sudden) kidney failure. The kidneys of most people with chronic kidney failure gradually lose function. On the other hand, acute kidney failure develops rapidly over a few hours or days in people who have it. Those who have already been admitted to a hospital or are critically ill and require intensive care are considered high risk. Acute kidney failure is almost always caused by another medical condition, an infection, or the use of kidney-harming medications. A variety of factors can cause kidney damage. A number of other serious conditions can exacerbate acute kidney failure.
COVID-19 Impact Analysis
In intensive care units (ICUs), 20 to 25 percent of patients with acute kidney injury (AKI) require renal replacement therapy (RRT). In the ICU, the mortality rate for patients with AKI requiring dialysis (AKI-RRT) is greater than 50%, which can be explained by the recent increase in age and the burden of comorbidities in critically ill patients. The COVID-19 pandemic, caused by the new coronavirus SARS-CoV-2, significantly impacted nephrology practice, resulting in increased demand for nephrologists and nephrology-specialized nurses RRT equipment and supplies. Knowing the incidence, characteristics, and outcomes of AKI linked to COVID-19 is critical for health planning. Hence, Covid-19 is expected to positively impact the global acute renal failure therapeutics market.
Acute Renal Failure Therapeutics Market Segment Analysis
Pre-renal Kidney Failure segment is expected to dominate the market growth
Prerenal AKI is a well-studied condition requiring early detection and treatment to avoid long-term consequences. The epidemiology, evaluation, and management of prerenal acute kidney injury are covered in this activity. It also explains how the interprofessional team can help patients with this condition get better care. Prerenal renal failure is caused by poor nephron perfusion, which results in a decrease in GFR. It stems from an imbalance in the delivery of nutrition and oxygen to the nephrons during increased energy demand. As a result, any condition that affects the systemic circulation or reduces renal perfusion can impair GFR. Autoregulatory functions are present in a healthy person, which aid in maintaining the GFR. However, these autoregulatory mechanisms may be insufficient to boost GFR in patients with a history of chronic kidney disease (CKD). Intravascular volume depletion, hypotension, sepsis, shock, over diuresis, heart failure, cirrhosis, bilateral renal artery stenosis/single functioning kidney, which is worsened by angiotensin-converting enzyme (ACE) inhibitors and other drugs (i.e., non-steroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, diuretics, etc.) are just a few of the causes.
Acute Renal Failure Therapeutics Market Geographical Analysis
North America region is expected to hold the largest market share in the global acute renal failure therapeutics market
Governments are increasingly pursuing research and development initiatives in the healthcare sector. In addition, a number of government agencies are planning to hold public awareness campaigns about infant healthcare. Such initiatives will eventually gain a lot of traction and are expected to drive market growth in this region. Companies are increasingly investing in acute renal failure treatment options. Strategic collaborations, the development of technologically advanced drugs, and acquisitions are some of the strategies used by key players to strengthen their market position. For instance, Mayo Clinic and Baxter International teamed up to create a renal care centre in the United States. This new centre of excellence will focus on patients with acute renal failure to improve patient outcomes.
Acute Renal Failure Therapeutics Market Competitive Landscape
Acute Renal Failure Therapeutics Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Fresenius Medical Care, B. Braun Melsungen AG, Pfizer Inc., Medtronic, Baxter, Teleflex Incorporated, Cook., Upsher-Smith Laboratories, LLC. , Dialife SA, Asahi Kasei Medical Co., Ltd.
Fresenius Medical Care
Overview: Fresenius Medical Care AG & Co. KGaA is a German healthcare company that provides dialysis services to patients through outpatient dialysis centers. The company primarily treats patients with end-stage renal disease (ESRD). The company has headquarters in Germany. And was founded in 1996.
Product Portfolio: Continuous renal replacement therapy (CRRT) uses special solutions and filters to clean the blood, mimicking the kidney's natural functions and maintaining body fluid levels. Fresenius Medical Care provides effective acute kidney injury treatment using a variety of therapies tailored to each patient's specific needs.
Frequently Asked Questions
What is the Projected CAGR value of the Acute Renal Failure Therapeutics Market?
Acute Renal Failure Therapeutics Market is expected to grow at a CAGR of 8.1% during the forecasting period 2023-2030.
Which region controlled the global market during 2023-2030?
North America region Controls the Acute Renal Failure Therapeutics Market during 2023-2030
Which is the fastest growing region in the Acute Renal Failure Therapeutics Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
